Company Overview and News


Add BIT
to your dashboard

Headline News

Biotron concludes patient recruitment for HIV-1 clinical trial

2017-07-27 proactiveinvestors.com.au
Biotron’s (ASX:BIT) shares were trading 5.5% higher intra-day after completing patient recruitment for the phase 2 HIV-1 clinical trial of its lead antiviral drug, BIT225.

Biotron shares rise on commencing promising HIV trial

2017-02-13 proactiveinvestors.com.au
Biotron (ASX:BIT) has commenced the Phase 2 human clinical trial of its lead antiviral drug BIT225 in patients with Human Immunodeficiency Virus (HIV-1) infection.

Appendix 4C - quarterly

2016-04-20 asx.com.au

$1.5 Million R&D Tax Rebate

2016-04-20 asx.com.au

Letter to Shareholders

2016-04-12 asx.com.au

Biotron Phase 2 Hepatitis C Trial Success

2016-03-17 prnewswire
NEW YORK, March 17, 2016 /PRNewswire/ -- Biotron Limited (ASX: BIT) confirms positive outcomes from its Phase 2 study of its first-in-class antiviral drug BIT225.

Phase 2 Hepatitis C Trial Success

2016-03-17 asx.com.au

Half Yearly Report and Accounts

2016-02-26 asx.com.au

Appendix 3B

2016-01-15 asx.com.au

Appendix 4C - quarterly

2016-01-15 asx.com.au

AGM Presentation

2015-11-24 asx.com.au

Results of Meeting

2015-11-24 asx.com.au

Appendix 4C - quarterly

2015-10-22 asx.com.au

Letter to Shareholders

2015-10-06 asx.com.au

Presentation to Investors

2015-10-06 asx.com.au

Annual Report to Shareholders

2015-08-28 asx.com.au